Phenylephrine, Long Time On Market For Hypotension, Goes To FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks counsel on whether elevation in blood pressure is sufficient clinical benefit to approve the literature-based NDA for West-Ward Pharmaceutical’s product, which is currently an unapproved drug.